FLT3 and acute myeloid leukemia: The increasing use of targeted therapies such as gilteritinib or midostaurin (tyrosine kinase inhibitors targeting FLT3 and other kinases) in FLT3-mutated AML makes the monitoring of this marker even more enticing.